Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor explains options for patients.

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way.

It’s official – Americans spent the same amount of money on weight loss injections as the country’s entire foreign aid budget in 2023. According to a study by the American Medical ...

A federal court in Texas has bolstered Novo Nordisk’s efforts to limit the production and sale of compounded versions of its GLP-1 drugs, Wegovy and Ozempic. Here are five notes: A federal ...

A large review of studies compared GLP-1 agonist medications, including semaglutide, for lowering people’s risk of cardiovascular problems. (Semaglutide is the active ingredient in Ozempic and ...

Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of ... active ingredient in diabetes drug Ozempic and weight-loss drug Wegovy ...

Even for those who have diabetes and want to lose weight, one of these medications would cover both issues, as they contain the same active ingredient. The side effects of Wegovy and Ozempic are ...